Longitudinal studies have shown that CSF-PGRN levels increase as AD progresses, correlating with neurodegenerative markers such as t-Tau, p-Tau181P, and cognitive decline, although their role as biomarkers remains debated [101,102]. Here, GRN is linked to Alzheimer disease.